本刊特点：CSCD核心期刊（2025-2026）,SCIE（2024版）,目次收录（知网）,外文期刊,
期刊基本信息
出版周期：双月刊 级别：核心期刊
主管部门：中国科学技术协会
主办单位：中国生物材料学会
编辑部：《再生生物材料（英文）》编辑部
中国国内刊号：CN51-1798
国际标准刊号：ISSN 2056-3418；EISSN 2056-3426
杂志社联系方式
地址：四川省成都市望江路29号生物材料楼《再生生物材料（英文）》编辑部
邮编：610064
微信公众号：Regenerative Biomaterials（RB-JOURNAL）
官方网站：https://academic.oup.com/rb
杂志征稿投稿要求
《再生生物材料（英文）》期刊介绍
【主办单位官网信息】
中国生物材料学会会刊Regenerative Biomaterials 《再生生物材料（英文）》是中国生物材料学会和牛津大学出版社合作出版的国际英文学术期刊，于2014年创刊。中国生物材料学会名誉理事长、四川大学张兴栋院士和美国得克萨斯大学奥斯汀分校Nicholas Peppas院士担任会刊共同主编，复旦大学丁建东教授担任会刊执行副主编，美国凯斯西储大学James Anderson院士、美国康涅狄克大学Cato Laurencin院士和浙江大学顾臻教授担任会刊副主编。会刊编委会由70余位国内外知名专家和学者组成。
会刊已被Scopus、SCI-E、PubMed Central、DOAJ、Ei和CSCD等数据库收录。2022年影响因子为6.7。在Web of Science 生物材料学科中位于1区。2019年入选“中国科技期刊卓越行动计划高起点新刊”。2022年在中科院期刊分区中位于工程技术1区Top。
欢迎广大读者登录会刊官网免费注册、订阅和投稿。
https://academic.oup.com/rb
《再生生物材料（英文）》的主要范围包括但不局限于以下内容：
• Design, synthesis, and evaluation of biomaterials for tissue engineering and regenerative medicine
• Nanotechnologies and novel processing for preparing biomimetic scaffolds
• Interaction of biomaterial with cells, especially with stem cells
• Regenerative mechanisms of tissue by using biomaterials and/or stem cells
• Drug/gene delivery materials and methods
• Clinical applications of regenerative biomaterials
• Scientific bases of evaluation and quality control of biomedical materials
• Surface modification of biomaterials
• Safety assessment of biomedical materials
• Stem cells fate controlled by materials signals
• Improvement of implanted medical devices
• Biomechanics of biomaterials and devices
• Regenerative engineering
《再生生物材料（英文）》作者须知
【杂志社官方网站信息】
Instructions to authors
Scope of the journal
Regenerative Biomaterials, the official journal of Chinese Society for Biomaterials is a fully open access, peer-reviewed journal. This journal is online only and aims to provide an international platform for researchers to share new ideas and research results in the field of biomaterials, especially the biomaterials in regenerative medicine. With its broad scope from the fundamental science of biomaterials to their potential clinical applications, the journal publishes high quality reviews, original research articles, communications, and perspectives.
The scope of Regenerative Biomaterials includes, but not limited to:
Design, synthesis, and evaluation of biomaterials for tissue engineering and regenerative medicine
Nanotechnologies and novel processing for preparing biomimetic scaffolds
Interaction of biomaterial with cells, especially with stem cells
Regenerative mechanisms of tissue by using biomaterials and/or stem cells
Drug/gene delivery materials and methods
Clinical applications of regenerative biomaterials
Scientific bases of evaluation and quality control of biomedical materials
Surface modification of biomaterials
Safety assessment of biomedical materials
Stem cells fate controlled by materials signals
Improvement of implanted medical devices
Biomechanics of biomaterials and devices
Regenerative engineering
Publication ethics
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
Authorship
All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version. Anyone who made major contributions to the writing of the manuscript should be listed as an author (e.g. “ghost writing” is prohibited by the Journal). Any other individuals who made less substantive contributions to the study or the writing of the manuscript should be listed in the acknowledgement section. Any change in authorship (including author order) after the initial manuscript submission must be approved in writing by all authors.
Authorship and 'Umbrella' groups
Many large collaborative studies are organized under a group name which represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should first list the author(s) of the article and follow this with 'on behalf of the GROUP NAME'. If necessary the names of the participants may be listed in the Acknowledgements section.
Originality
By submitting your manuscript to the journal it is understood that this it is an original manuscript and is unpublished work and is not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the journal. Manuscripts submitted to the journal may be checked for originality using anti-plagiarism software.
Conflicts of interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
Experimental ethics
Animal experiments
When reporting animal experiments authors should indicate whether the institution’s, national research council’s, or any other law on the care and use of laboratory animals was followed.
Human subjects
When reporting on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. Manuscripts should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that the design of the work has been approved by local ethical committees or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.
Peer review process
All submissions to the journal are initially reviewed by one of the Editors. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process.
Manuscripts that are not instantly rejected are sent out for peer review, usually to two independent reviewers. Based on the feedback from these reviewers and the Editors’ judgment a decision is given on the manuscript. The average time from submission to first decision is 6 weeks.
If a paper is not acceptable in its present form, we will pass on suggestions for revisions to the author.
Material disclaimer
The opinions expressed in Regenerative Biomaterials are those of the authors and contributors, and do not necessarily reflect those of the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated.
……
更多详情：
https://academic.oup.com/rb/pages/General-Instructions